[1]杨清慧,张 雯,刘清欣,等.肝癌伴下腔静脉癌栓行TACE联合下腔静脉放射性支架或裸支架治疗的对照研究 [J].介入放射学杂志,2017,(07):607-612.
 YANG Qinghui,ZHANG Wen,LIU Qingxin,et al.TACE combined with implantation of IVC irradiation stent or bare stent for the treatment of HCC complicated by IVCTT: a comparative study[J].journal interventional radiology,2017,(07):607-612.
点击复制

肝癌伴下腔静脉癌栓行TACE联合下腔静脉放射性支架或裸支架治疗的对照研究 



()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年07期
页码:
607-612
栏目:
肿瘤介入
出版日期:
2017-07-25

文章信息/Info

Title:
TACE combined with implantation of IVC irradiation stent or bare stent for the treatment of HCC complicated by IVCTT: a comparative study
作者:
杨清慧 张 雯 刘清欣 刘凌晓 王建华 颜志平 罗剑钧
Author(s):
YANG Qinghui ZHANG Wen LIU Qingxin LIU Lingxiao WANG Jianhua YAN Zhiping LUO Jianjun
Department of Interventional Radiology, Affiliated Zhongshan Hospital of Fudan University, Shanghai Institute of Medical Imaging, Shanghai 20032, China
关键词:
【关键字】 125I 肝细胞肝癌 下腔静脉近程放疗
文献标志码:
A
摘要:
【摘要】 目的 探讨TACE联合下腔静脉放射性支架植入治疗肝细胞肝癌伴下腔静脉癌栓的安全性及有效性。方法 对61例肝细胞肝癌伴下腔静脉癌栓患者的资料行回顾性分析,放射性支架采用125I粒子条捆载裸支架的方法,共对33例患者采用此方法(A组),28例患者植入裸支架(B组)。采用倾向性评分匹配(propensity score matching)对原数据进行后随机化分析以减少选择性偏倚,对两组患者的生存期,症状缓解率及不良反应进行对照分析。结果 两组患者术后不良反应发生率相仿,均采用内科对症处理。A组患者较B组显示更长的生存期优势,A组中位生存时间(203.0±28.1) d, B组(93.0±24.3) d(P=0.006),倾向性评分匹配后(24对)A组(200±31) d, B组(66.0±23) d(P=0.019),A组水肿缓解率97.0%,B组为96.4%,多因素分析显示放射性支架植入与肿瘤客观有效率为患者预后好的独立性影响因素。结论 TACE联合放射性支架植入对治疗肝细胞肝癌伴下腔静脉癌栓安全有效,可能延长患者生存时间。

参考文献/References:

[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65: 87- 108.
[2] Tsuzuki T, Ogata Y, Iida S, et al. Hepatic resection in 125 patients[J]. Arch Surg, 1984, 119: 1025- 1032.
[3] Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[J]. Hepatology, 1999, 29: 62- 67.
[4] Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center[J]. Ann Surg, 1999, 229: 790- 799.
[5] Li AJ, Zhou WP, Lin C, et al. Surgical treatment of hepatocellular carcinoma with inferior vena cava tumor thrombus: a new classification for surgical guidance[J]. Hepatobiliary Pancreat Dis Int, 2013, 12: 263- 269.
[6] Hemming AW, Mekeel KL, Zendejas I, et al. Resection of the liver and inferior vena cava for hepatic malignancy[J]. J Am Coll Surg, 2013, 217: 115- 124.
[7] Jung H, Lee KU, Shin WY, et al. Treatment outcomes of surgical resection for hepatocellular carcinoma with inferior vena cava invasion and/or thrombosis[J]. Hepatogastroenterology, 2011, 58: 1694- 1699.
[8] Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification[J]. Semin Liver Dis, 1999, 19: 329- 338.
[9] Yoo DJ, Kim KM, Jin YJ, et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?[J]. J Gastroenterol Hepatol, 2011, 26: 145- 154.
[10] Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258: 627- 634.
[11] Chern MC, Chuang VP, Cheng T, et al. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors[J]. Cardiovasc Intervent Radiol, 2008, 31: 735- 744.
[12] Xi M, Zhang L, Zhao L, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis[J]. PLoS One, 2013, 8:e63864.
[13] Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and three- dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus[J]. Int J Radiat Oncol Biol Phys, 2010, 78: 180- 187.
[14] Sugiyama S, Beppu T, Ishiko T, et al. Efficacy of radiotherapy for PV and IVC tumor thrombosis in unresectable HCC[J]. Hepatogastroenterology, 2007, 54: 1779- 1782.
[15] Kudo H, Yata Y, Orihara T, et al. Malignant inferior vena cava syndrome[J]. Intern Med, 2006, 45: 219- 220.
[16] Brountzos EN, Binkert CA, Panagiotou IE, et al. Clinical outcome after intrahepatic venous stent placement for malignant inferior vena cava syndrome[J]. Cardiovasc Intervent Radiol, 2004, 27: 129- 136.
[17] Fletcher WS, Lakin PC, Pommier RF. Results of treatment of inferior vena cava syndrome with expandable metallic stents[J]. Arch Surg, 1998, 133: 935- 938.
[18] Zhang W, Yan Z, Luo J, et al. Iodine- 125 seeds strand for treatment of tumor thrombus in inferior vena cava: an experimental study in a rabbit model[J]. Cardiovasc Intervent Radiol, 2013, 36: 1371- 1382.
[19] Chen Y, Wang XL, Yan ZP, et al. The use of 125I seed strands for intraluminal brachytherapy of malignant obstructive jaundice[J]. Cancer Biother Radiopharm, 2012, 27: 317- 323.
[20] Luo J, Yan Z, Liu Q, et al. Endovascular placement of iodine- 125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein[J]. J Vasc Interv Radiol, 2011, 22: 479- 489.
[21] Yang MJ, Fang ZT, Yan ZP, et al. Transarterial chemoembolisation(TACE) combined with endovascular implantation of an iodine- 125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two - arm, randomised clinical trial[J]. J Cancer Res Clin Oncol, 2014, 140: 211- 219.
[22] 杨敏捷, 罗剑钧, 刘清欣, 等. 125I粒子条剂量分布研究[J]. 介入放射学杂志, 2015, 24: 59- 63.
[23] 李文会, 罗剑钧, 戴真煜, 等. 腔内近距离放疗联合及支架植入治疗恶性胆道梗阻[J]. 介入放射学杂志, 2015, 24: 215- 218.
[24] 刘清欣, 颜志平, 李 说, 等. 125I粒子条联合门静脉支架及化疗栓塞治疗原发性肝癌合并门静脉癌栓[J]. 介入放射学杂志, 2009, 18: 593- 595.
[25] 郝红军, 张兴仕, 金 鑫, 等. 支架联合125I粒子条植入治疗肝癌所致下腔静脉恶性梗阻20例[J]. 介入放射学杂志, 2016, 25: 538- 542.
[26] 吴林霖, 颜志平, 张 雯, 等. 经动脉灌注化疗联合125I粒子条治疗原发性肝癌合并门脉癌栓的疗效分析[J]. 介入放射学杂志, 2015, 24: 776- 780.
[27] 方主亭, 颜志平, 罗剑钧, 等. TACE联合与未联合腔内125I粒子条置入治疗肝癌伴广泛性门静脉癌栓[J]. 中华介入放射学电子杂志, 2013, 1: 8- 13.
[28] Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2003, 362: 1907- 1917.
[29] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30: 52- 60.
[30] Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine[J]. Med Phys, 1995, 22: 209- 234.
[31] Lin ZY, Lin J, Lin C, et al. 1.5 T conventional MR- guided iodine- 125 interstitial implants for hepatocellular carcinoma: feasibility and preliminary clinical experience[J]. Eur J Radiol, 2012, 81: 1420- 1425.
[32] Zhang FJ, Li CX, Jiao DC, et al. CT guided 125Iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma[J]. Chin Med J, 2008, 121: 2410- 2414.
[33] Nag S, Dehaan M, Scruggs G, et al. Long term follow- up of patients of intrahepatic malignancies treated with iodine- 125 brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2005, 64: 736- 744.
[34] Sidawy AN, Weiswasser JM, Waksman R. Peripheral vascular brachytherapy[J]. J Vasc Surg, 2002, 35: 1041- 1047.
[35] Sindelar WF, Kinsella TJ. Normal tissue tolerance to intraoperative radiotherapy[J]. Surg Oncol Clin N Am, 2003, 12: 925- 942.

相似文献/References:

[1]高德,李茂全.肝、肾复合肿瘤术后预防性动脉内灌注化疗1例[J].介入放射学杂志,1996,(01):6.
[2]秦永福,宁路江,齐颖,等.原发性肝癌合并门脉癌栓的经导管碘油化疗栓塞[J].介入放射学杂志,1996,(04):223.
[3]姜卫剑,吴朝阳,吕胜吉,等.微导管栓塞技术在小肝癌中的应用[J].介入放射学杂志,2000,(02):82.
[4]杨国威,张 巍,钱 晟,等.热损伤对肝细胞肝癌细胞增殖及侵袭转移特性影响的实验研究 [J].介入放射学杂志,2017,(05):436.
 YANG Guowei,ZHANG Wei,QIAN Sheng,et al.The effect of thermal damage on the cell proliferation and invasive metastasis of HCC: an experimental study in vitro[J].journal interventional radiology,2017,(07):436.
[5]洪立立,郭 志,司同国,等.高强度聚焦超声补救治疗TACE失败肝癌的临床应用[J].介入放射学杂志,2014,(12):1044.
 HONG Li li,GUO Zhi,SI Tong guo,et al.High intensity focused ultrasound used as a salvage therapy for hepatocellular carcinoma that failed to respond to transcather arterial chemoembolization[J].journal interventional radiology,2014,(07):1044.
[6]付 元,纪建松,涂建飞,等.TACE联合RFA及索拉菲尼在肝癌外科术后复发治疗中的临床应用[J].介入放射学杂志,2015,(12):1067.
 FU Yuan,JI Jian- song,TU Jian- fei,et al.The clinical application of TACE combined with RFA and sorafenib in treating recurrent hepatocellular carcinoma after surgery[J].journal interventional radiology,2015,(07):1067.
[7]罗 君,邵国良,郑家平,等.原发性肝癌肝动脉化疗栓塞术后腹痛的发生规律及影响因素 [J].介入放射学杂志,2017,(07):613.
 LUO Jun,SHAO Guoliang,ZHENG Jiaping,et al.The regularity of abdominal pain and its influence factors in patients with primary hepatocellular carcinoma after receiving TACE[J].journal interventional radiology,2017,(07):613.
[8]褚 亚,周 石,王黎洲,等.磷脂酶Cβ1上调表达与肝细胞肝癌增殖和预后相关 [J].介入放射学杂志,2018,27(01):29.
 CHU Ya,ZHOU Shi,WANG Lizhou,et al.The correlation of up- regulated expression of PLCβ1 with hepatocellular carcinoma cell proliferation and prognosis[J].journal interventional radiology,2018,27(07):29.
[9]管 阳,刘凤永,樊庆胜,等.SD大鼠McA- RH7777细胞系肝癌模型构建及其特点[J].介入放射学杂志,2018,27(06):549.
 GUAN Yang,LIU Fengyong,FAN Qingsheng,et al.The establishment of SD rat McA- RH7777 cell hepatocellular carcinoma model and its characteristics[J].journal interventional radiology,2018,27(07):549.
[10]刘 源,李 曦,张莉敏,等.足头向穿刺路径对近膈顶肝癌冷冻消融的临床应用 [J].介入放射学杂志,2018,27(08):775.
 LIU Yuan,LI Xi,ZHANG Limin,et al.Clinical application of foot- head direction puncturing technique in performing cryoablation of subphrenic hepatocellular carcinoma[J].journal interventional radiology,2018,27(07):775.

备注/Memo

备注/Memo:
(收稿日期:2016-09-25)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2017-07-12